Vimarsana
Biggest News Aggregation in the World

Page 12 - Alpn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpn Today - Breaking & Trending Today

Alpine Immune Sciences Inc.: Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022 - Vimarsana News

Alpine Immune Sciences Inc.: Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc's - - Ongoing phase 1 study demonstrates highly encouraging preliminary

Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%. […]

Alpine Immune Sciences (NASDAQ:ALPN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ […]

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.06 EPS - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ:ALPN […]

Zacks: Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Will Post Quarterly Sales of $13.35 Million - Vimarsana News

Zacks: Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Will Post Quarterly Sales of $13.35 Million

Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will post sales of $13.35 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $5.93 million to $20.00 million. Alpine Immune Sciences posted sales of $3.20 million in […]